NEVRO CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.02 USD | +5.08% |
|
+31.54% | -53.49% |
| 01:44pm | Truist Lowers Price Target on Nevro to $10 From $11, Maintains Hold Rating | MT |
| 15/07 | Morgan Stanley Cuts Price Target on Nevro to $9 From $14, Keeps Equalweight Rating | MT |
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Calendar
06/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
16
Last Close Price
9.54
USD
Average target price
14.23
USD
Spread / Average Target
+49.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.49% | 35Cr | |
| -6.73% | 18TCr | |
| -5.72% | 9.88TCr | |
| -5.52% | 6.53TCr | |
| +15.46% | 4.54TCr | |
| -7.20% | 4.49TCr | |
| +9.63% | 4.38TCr | |
| +13.50% | 2.9TCr | |
| +19.39% | 2.56TCr | |
| -6.62% | 2.33TCr |
- Stock Market
- Equities
- NVRO Stock
- News Nevro Corp.
- Truist Lowers Price Target on Nevro to $10 From $11, Maintains Hold Rating
